ClinicalTrials.gg
CompletedNCT06905327Updated Jul 9, 2026

A Study to Evaluate the Safety of QCZ484 in Healthy and Mild Hypertensive Subjects

A Phase 1 interventional study of QCZ484 and Placebo in Mild Hypertension, sponsored by Novartis Pharmaceuticals. Completed at 4 sites in 2 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-09.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2024, 2 years 1 month ago, and no results have been posted to the registry.
  • Registered 2 years after the study started (first participant enrolled Mar 2023, registered Mar 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 227 studies in Hypertension by Novartis — 4 open to participants now, 5 under way, none of them phase 3. Hypertension · Novartis.

Enrollment
187th of 222
56 · median 309
Started
2023
with 2 others
Phase 1
17 of 227
1 open now
Registered
223rd of 227
by date

Among the 227 studies in Hypertension by Novartis, this one is the 187th largest by enrollment of the 222 interventional ones that give a count, is one of 3 that started in 2023, is one of 17 in phase 1, and was the 223rd registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.

Browse Hypertension studies →

Open to participants now

4 of the 227 studies in Hypertension by Novartis are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 227 studies in Hypertension by Novartis, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled study including Part A single ascending dose (SAD) in healthy subjects and Part B single dose in subjects with mild hypertension.

Read the detailed description

Phase 1, multicenter, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of QCZ484. In Part A, single ascending doses of QCZ484 are tested in healthy subjects, while in Part B, single doses of QCZ484 are tested in subjects with mild hypertension. One dose of QCZ484 is administered subcutaneously.

This study was started by Argo Biopharma, and global sponsorship was transferred to Novartis.

03

Conditions studied

  • Mild Hypertension

Browse trials for

Keywords

  • Hypertension
  • QCZ484
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males or females aged 18 to 60 years, inclusive, at the time of . (Part A only).
  • Males or females aged 18 to 72 years, inclusive, at the time of informed consent (Part B only).
  • (BMI) >= 18 and \<= 32 kg/m2 and body weight >50 kg (Part A only).
  • Body mass index (BMI) >=18 and \<=35 kg/m2 and body weight >50 kg (Part B only).
  • Triplicate 12-lead (ECG) after >5 minutes resting without findings at screening and Day -1.
  • Mean sitting systolic blood pressure (SBP) of >=130 and \<160 mm Hg (Part B only).

Exclusion criteria

Exclusion Criteria:

  • History of hypotension or orthostatic hypotension.
  • History of syncope within 1 year.
  • SBP \<90 mmHg or DBP \<60 mm Hg at screening (Part A only).
  • Clinical laboratory findings outside of range are deemed by the investigator at screening.
  • Any liver function panel analyte value > 1.2 × (ULN) at screening.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Part A: QCZ484 50 mg

    Healthy Cohort: single dose

    Drug: QCZ484

  • Experimental
    Part A: QCZ484 150 mg

    Healthy Cohort: single dose

    Drug: QCZ484

  • Experimental
    Part A: QCZ484 300 mg

    Healthy Cohort: single dose

    Drug: QCZ484

  • Experimental
    Part A: QCZ484 600 mg

    Healthy Cohort: single dose

    Drug: QCZ484

  • Placebo comparator
    Part A: QCZ484 Placebo

    Healthy Cohort: single dose

    Drug: Placebo

  • Experimental
    Part B: QCZ484 150 mg

    Hypertension Cohort: single dose

    Drug: QCZ484

  • Experimental
    Part B: QCZ484 300 mg

    Hypertension Cohort: single dose

    Drug: QCZ484

  • Experimental
    Part B: QCZ484 600 mg

    Hypertension Cohort: single dose

    Drug: QCZ484

  • Placebo comparator
    Part B: QCZ484 Placebo

    Hypertension Cohort: single dose

    Drug: Placebo

Interventions

  • DrugQCZ484

    doses of 50, 150, 300 or 600 mg via subcutaneous injection

  • DrugPlacebo

    via subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Number of adverse events (AEs)

    Overall number of AEs, severity, and relationship to study treatment per treatment group.

    Time frame: Part A: up to 12 weeks post dose. Part B: up to 8 weeks post dose.

  2. Number of participants with abnormalities in any laboratory parameter

    Safety laboratory data (blood chemistry, hematology, coagulation, and urinalysis)

    Time frame: Part A: up to 12 weeks post dose. Part B: up to 8 weeks post dose

Secondary outcomes

  1. Number of AEs

    Overall number of AEs, severity and relationship to study treatment per treatment group

    Time frame: up to 48 weeks post dose

  2. Number of participants with abnormalities in any laboratory parameter

    Safety laboratory data (blood chemistry, hematology, coagulation, and urinalysis)

    Time frame: up to 48 weeks post dose

  3. Plasma pharmacokinetics of QCZ484 and metabolites - Cmax

    Measured by Cmax - The maximum plasma concentration of QCZ484 and of potential metabolites

    Time frame: Day 1; up to Day 8

  4. Plasma pharmacokinetics of QCZ484 - Tmax

    Measured by Tmax - Time to Reach the Maximum Concentration After Drug Administration of QCZ484

    Time frame: Day 1; up to Day 8

  5. Plasma pharmacokinetics of QCZ484 and metabolites - AUC0-48

    Measured by AUC - Area under the curve versus time curve of QCZ484 from 0 to 48 hours (AUC0-48) and of potential metabolites

    Time frame: Day 1; up to Day 8

  6. Plasma pharmacokinetics of QCZ484 - AUC0-inf

    Measured by AUC - Area under the curve versus time curve of QCZ484 from 0 to infinity (AUC0-inf)

    Time frame: Day 1; up to Day 8

  7. Plasma pharmacokinetics of QCZ484 - T1/2

    Measured by T1/2 - The elimination half-life of QCZ484

    Time frame: Day 1; up to Day 8

  8. Urine pharmacokinetics of QCZ484

    Measured by urine concentration of QCZ484 up to 24 hours post dose

    Time frame: Day 1; up to Day 2

  9. Change from baseline in serum angiotensinogen (AGT) level

    Measured by serum AGT level

    Time frame: up to 48 weeks post dose

07

Study locations

4 sites
  • Novartis Investigative Site
    Herston, Queensland 4006, Australia
  • Novartis Investigative Site
    Morayfield, Queensland 4506, Australia
  • Novartis Investigative Site
    Adelaide, 5000, Australia
  • Novartis Investigative Site
    Auckland, 0622, New Zealand
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Sep 2024, 18 months.

Of 132 industry-sponsored phase 1 interventional studies under Hypertension, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 18 months is above that.

Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 1 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2025
First posted
Apr 1, 2025
StartActual
Mar 8, 2023
Primary completionActual
Sep 25, 2024
CompletionActual
Jul 1, 2025
Last update
Jul 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06905327
Responsible party
Sponsor
First posted
Apr 1, 2025
Start date
Mar 8, 2023
Primary completion
Sep 25, 2024
Completion
Jul 1, 2025
Last update
Jul 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: QCZ484

Start the discussion